Search clinical trials for: Pethema

Total 100 results

PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
PETHEMA Foundation

Not yet recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL (LALPh2022)

Lymphoblastic Leukemia | Adult ALL | Philadelphia-Positive ALL
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
PETHEMA Foundation
Bristol-Myers Squibb; Sanofi; Adknoma; Start from scratch

Not yet recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (GEM21menos65)

Newly Diagnosed Multiple Myeloma

Spain
PETHEMA Foundation
Janssen-Cilag, S.A.; Celgene-BMS; LIDESEC

Not yet recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Multiple Myeloma

Spain
PETHEMA Foundation
GlaxoSmithKline

Recruiting

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Spain
PETHEMA Foundation
Janssen, LP; Adknoma Health Research

Recruiting

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Multiple Myeloma | Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Spain
PETHEMA Foundation
Adknoma Health Research

Recruiting

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Relapsed Multiple Myeloma

Spain
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Recruiting

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Mature B-Cell Leukemia Burkitt Type | Burkitt Lymphoma (BL) | Unclassifiable Lymphoma Between DCBL and BL

Spain
PETHEMA Foundation
GlaxoSmithKline

Recruiting

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Multiple Myeloma

Spain
PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
PETHEMA Foundation

Recruiting

Molecular Diagnostic Platform for AML

Acute Myeloid Leukemia (AML)

Spain
PETHEMA Foundation

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Refractory Multiple Myeloma

Spain
PETHEMA Foundation

Recruiting

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Lymphoblastic Lymphoma

Spain
PETHEMA Foundation

Recruiting

Epidemiologic Registry PETHEMA LMA 2015

AML

Spain
PETHEMA Foundation

Recruiting

Clinical Guidelines for APL Treatment

APL

Spain
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
PETHEMA Foundation

Recruiting

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Acute Lymphoblastic Leukemia Ph Positive

Spain
PETHEMA Foundation

Recruiting

Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Recruiting

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Recruiting

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Acute Myeloblastic Leukemia

Spain
Technische Universität Dresden
German Federal Ministry of Education and Research; Groupe Francophone des Myelodysplasies and other collaborators

Active, not recruiting

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

Acute Promyelocytic Leukemia

France, Germany, Italy, Netherlands, Spain
PETHEMA Foundation

Active, not recruiting

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Chronic Lymphocytic Leukemia

Spain
PETHEMA Foundation
Novartis

Completed

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Active, not recruiting

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Newly Diagnosed Multiple Myeloma

Spain
PETHEMA Foundation
Celgene Corporation; Amgen

Active, not recruiting

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Spain
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Dynamic Science S.L.

Active, not recruiting

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (PEVOLAM)

Leukemia, Myeloid, Acute

Spain, Portugal
PETHEMA Foundation

Completed

Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia (LAMVYX)

Newly Diagnosed Secondary or High Risk AML

Spain
PETHEMA Foundation

Active, not recruiting

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia- Binet Staging System

Spain
PETHEMA Foundation

Active, not recruiting

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Multiple Myeloma

Spain
PETHEMA Foundation

Terminated

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL

Spain
PETHEMA Foundation
Celgene Corporation; Array BioPharma

Completed

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Multiple Myeloma

Spain
PETHEMA Foundation
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Syntax for Science, S.L

Active, not recruiting

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Active, not recruiting

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia (PONALFIL)

ALL

Spain
PETHEMA Foundation
Cabyc, S.L.

Active, not recruiting

GEM-CLARIDEX: Ld vs BiRd (GEM-CLARIDEX)

Multiple Myeloma

Spain
PETHEMA Foundation
Daiichi Sankyo, Inc.; Dynamic Science S.L.

Active, not recruiting

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Terminated

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Completed

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

Relapsed and Refractory Multiple Myeloma

Spain
PETHEMA Foundation

Completed

VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years

AML

Spain
PETHEMA Foundation

Completed

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML (FLAGINEXOR)

Acute Myeloid Leukemia

Spain
PETHEMA Foundation
Merck Sharp & Dohme LLC; Adknoma Health Research

Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

CML Treated With Bosutinib After Relapse (BOSTRO)

Chronic Myeloblastic Leukaemia

Spain
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; GELCAB

Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Lymphoma

Spain
PETHEMA Foundation

Completed

Treatment of High Risk Adult Acute Lymphoblastic Leukemia (LAL-AR/2003)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation
Novartis; Dynamic Solutions

Completed

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse (AZABACHE)

Multiple Myeloma

Spain
PETHEMA Foundation
Dynamic Solutions

Completed

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (FLUGAZA)

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Completed

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Acute Lymphobkastic Leukemia

Spain

3

Subscribe